TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10606453
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam irradiation (seven treatment sessions)
Study: 10606453
Drug: Sham radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham radiation (one sham treatment session)
Study: 31477558
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg daily for 8 weeks (run-in phase)
Study: 31477558
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg or 300 mg or matched placebo (double-blind randomisation)
Study: 25172777
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg
Study: 17692271
Drug: Valacyclovir (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (500 mg tablet daily)
Study: 17692271
Drug: Acyclovir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (400 mg tablet twice daily)
Study: 11953546
Drug: Functional Electric
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electric Stimulation (FES) therapy for short-duration hemiplegia, 6 hours a day for 6 weeks.
Study: 11953546
Drug: Functional Electric
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electric Stimulation (FES) therapy for long-duration hemiplegia, 6 hours a day for 6 weeks.
Study: 11953546
Drug: Second 6-week
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Second 6-week FES therapy after the first 6-week therapy for both short and long-duration groups.
Study: 9525433
Drug: Nonoxynol-9 (N-9)
Normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoxynol-9 (N-9) 100 mg daily for 1 week
Study: 2676652
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg fenticonazole (single administration)
Study: 2676652
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg clotrimazole (single administration)
Study: 30584131
Drug: L-Arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine supplementation
Study: 29081128
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy and high pressure oxygen (Control)
Study: 25935844
Drug: Vapocoolant spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapocoolant spray (control)
Study: 25935844
Drug: Vapocoolant spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapocoolant spray and pop of an empty J‐Tip (sham)
Study: 19079970
Drug: Conventional assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional assisted reproduction treatment (Control)
Study: 15823628
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with diet, anti-hypertensive or antidiabetic drugs
Study: 8746880
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg estriol vaginal suppositories
Study: 8746880
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg estriol vaginal suppositories
Study: 28779007
Drug: Dexamethasone implants
Normalized name: dexamethasone Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone implants
Study: 22648841
Drug: HIIC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIIC + Parenteral Nutrition (HIIC+PN)
Study: 20931801
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive drospirenone/ethinyl E2 (group 1)
Study: 20931801
Drug: Norelgestromin/ethinyl E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norelgestromin/ethinyl E2 transdermal patch (group 2)
Study: 2020272
Drug: Naloxone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (20 mg)
Study: 28062296
Drug: Atorvastatin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin after 8 weeks
Study: 25091668
Drug: Withholding breastfeeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding breastfeeding during the 30 min prior to and after each vaccine dose
Study: 25091668
Drug: Breastfeeding during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breastfeeding during the 30 min prior to and after each vaccine dose
Study: 22815003
Drug: Esmolol drip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol drip (0.2‐0.5 mg/kg bolus followed by continuous infusion of 212.5 ± 63.5 mg/h to 272.5 ± 89.5 mg/h over 24 hours)
Study: 17156345
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical steroid (extra-fine inhaled beclomethasone 400 mcg/day and intranasal beclomethasone 200 mcg/day)
Study: 17156345
Drug: Combined mediator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined mediator antagonism (montelukast 10 mg and cetirizine 10 mg)
Study: 10612317
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (120 mg/d)
Study: 7675241
Drug: 0.5 mg/kg/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg/hr levodopa infusion
Study: 7675241
Drug: 1.0 mg/kg/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg/hr levodopa infusion
Study: 7675241
Drug: 0.0 mg/kg/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 mg/kg/hr levodopa infusion (placebo)
Study: 7002059
Drug: Intrathecal antitetanus
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal antitetanus serum with steroid
Study: 24565542
Drug: Combination budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination budesonide/formoterol as maintenance and reliever therapy
Study: 24565542
Drug: Combination budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination budesonide/formoterol as maintenance treatment with albuterol as reliever
Study: 10396923
Drug: Regular outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular outpatient treatment (3 months)
Study: 10396923
Drug: Extended outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended outpatient treatment (6 months)
Study: 7993599
Drug: Sealants applied
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealants applied with a drying agent
Study: 7993599
Drug: Sealants applied
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealants applied without a drying agent
Study: 4881341
Drug: Aqueous vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aqueous vasopressin injection (Pitressin)
Study: 29637896
Drug: Mg lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg lactate (MgLact2) supplementation
Study: 22134732
Drug: Antiresorptive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive agents combined with repeated PVPs
Study: 19920001
Drug: Revascularization plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revascularization plus intensive medical therapy
Study: 19920001
Drug: Insulin provision
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin provision therapy
Study: 9868028
Drug: Musical relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Musical relaxation therapy
Study: 3646613
Drug: Self-administered pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered pain medication
Study: 3646613
Drug: Nurse-administered pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered pain medication
Study: 29940151
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment arm (blood pressure target <= 120 mmHg)
Study: 29940151
Drug: Combined effect
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined effect of pulse pressure and treatment intensity
Study: 25137430
Drug: Dexmedetomidine continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine continuous infusion at a rate of 0.4 μg kg(‐1) hour(‐1)
Study: 16796717
Drug: Pulse corticosteroid
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse corticosteroid therapy
Study: 16796717
Drug: Randomized clinical
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized clinical trial of biopsy and corticosteroid therapy
Study: 9020413
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 10 mg plus terbutaline 0.5 mg (group A)
Study: 9020413
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus terbutaline 0.5 mg (group B)
Study: 1413302
Drug: Gentamicin sulfate,
Normalized name: Gentamicin Sulfate, Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin sulfate, 80 mg, administered 8-hourly for a total of three doses, starting just prior to the operation
Study: 4042543
Drug: Alcohol (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.9 g/kg)
Study: 4042543
Drug: Placebo (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (400 ml of orange juice)
Study: 31206016
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg) for 24 weeks
Study: 31206016
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg) for 24 weeks
Study: 26871968
Drug: Bismuth potassium
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin (1.0 g), and furazolidone (100 mg) twice daily for 14 days with left lateral horizontal position for 30 min after dosing (GS group 1)
Study: 26871968
Drug: Bismuth potassium
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin (1.0 g), and furazolidone (100 mg) twice daily for 14 days (GS group 2)
Study: 25521726
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg/day
Study: 20849620
Drug: 8 or
Normalized name: K-8 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 or 16 fluid ounces of vegetable juice daily
Study: 20849620
Drug: 0 fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 fluid ounces of vegetable juice daily (Control)
Study: 17761704
Drug: Dose intensified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose intensified E (epirubicin) followed by taxane
Study: 15755847
Drug: Thyroxine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine treatment (n = 99; initial dose 8 microg/kg)
Study: 2012585
Drug: Creative novation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creative novation behaviour therapy (long-term individual therapy, group therapy, bibliotherapy plus short-term individual treatment)
Study: 6665837
Drug: Tinidazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (40 mg/kg body-weight in one daily dose for five days)
Study: 6665837
Drug: Tinidazole plus
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole plus diloxanide furoate (tinidazole at 40 mg/kg body-weight in one daily dose for five days and diloxanide furoate at 20 mg/kg body-weight divided into three daily doses for 10 days)
Study: 30051499
Drug: Dexamethasone 0.75
Normalized name: dexamethasone 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.75 mg/d
Study: 30051499
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no extra treatment)
Study: 25033789
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) 1200 mg/day
Study: 25033789
Drug: Ginseng 200
Normalized name: ginseng 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng 200 mg/day
Study: 22441301
Drug: aranidipine 5-10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aranidipine 5-10 mg/d (n = 118)
Study: 22441301
Drug: amlodipine 5-10
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5-10 mg/d (n = 118)
Study: 20122576
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with statins for at least 6 months (group B)
Study: 20122576
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with statins (group A)
Study: 12165574
Drug: TRH (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH (400 micro g every 8 hours up to 4 doses)
Study: 10064126
Drug: Hormone analogue
Normalized name: Melanocyte stimulating hormone analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone analogue (2.5 mg Livial) plus 800 mg calcium
Study: 10064126
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 800 mg calcium
Study: 18611062
Drug: Aripiprazole 15
Normalized name: aripiprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 15 mg (hepatic impairment study)
Study: 18611062
Drug: Aripiprazole 15
Normalized name: aripiprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 15 mg (renal impairment study)
Study: 10591309
Drug: Methylphenidate (Ritalin)
Normalized name: methylphenidate Oral Tablet [Ritalin]
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (Ritalin) hydrochloride at doses of 0.3 mg/kg or 0.6 mg/kg
Study: 8901800
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (50 mg on alternate days)
Study: 1831585
Drug: Enoximone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 0.5 mg/kg bolus followed by 2.5 micrograms/kg/min maintenance infusion
Study: 1831585
Drug: Enoximone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 0.5 mg/kg bolus followed by 5.0 micrograms/kg/min maintenance infusion
Study: 1831585
Drug: Enoximone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 0.5 mg/kg bolus followed by 10.0 micrograms/kg/min maintenance infusion
Study: 1831585
Drug: Enoximone 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 5.0 micrograms/kg/min maintenance infusion without loading dose
Study: 6344645
Drug: Orthokeratological (OK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthokeratological (OK) treatment
Study: 18722511
Drug: Moxifloxacin (preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (preventive antibacterial therapy)
Study: 16104989
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (n=40)
Study: 12401624
Drug: 0.15% ropivacaine/fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% ropivacaine/fentanyl 5 micro g/mL
Study: 12401624
Drug: 0.1% bupivacaine/fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bupivacaine/fentanyl 5 micro g/mL
Study: 12401624
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine consumption
Study: 6107232
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg iv
Study: 6107232
Drug: Furosemide 80
Normalized name: furosemide 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 80 mg po
Study: 22079079
Drug: 5%, 10%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5%, 10%, 15%, or 20% W(80)5EC combined with 4 or 10 μg strain‐specific Fluzone(®) HA
Study: 22079079
Drug: 20% W(80)5EC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% W(80)5EC combined with 10 μg strain‐specific HA
Study: 22079079
Drug: Intranasal PBS
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal PBS
Study: 22079079
Drug: Intranasal Fluzone(®)
Normalized name: Fluzone 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Fluzone(®)
Study: 22079079
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg strain‐specific intramuscular Fluzone(®)
Study: 20580029
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) - conjugated equine estrogen 0.625 mg/d with or without medroxyprogesterone acetate 2.5 mg/d
Study: 17610100
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day CLA plus 2 g/day SFO
Study: 17610100
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day CLA
Study: 17610100
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day safflower oil (SFO)
Study: 8578800
Drug: rgp160 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rgp160 vaccine in two accelerated schedules (Groups 1 and 2)
Study: 8578800
Drug: rgp160 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rgp160 vaccine at 0, 1, 6, and 12 months (Groups 3 and 4)
Study: 1774408
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of midazolam and alfentanil
Study: 7037105
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection of oesophageal varices (group 2)
Study: 29338151
Drug: Oral prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prolonged-release oxycodone/naloxone (OXN) 10 +10 +5 mg every 12 hours
Study: 29338151
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine patient-controlled analgesia (IVPCA) 2 mg bolus, no basal infusion
Study: 29338151
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine patient-controlled analgesia (IVPCA)
Study: 25335250
Drug: Estazolam tablets
Normalized name: Estazolam Tablets
DrugBank: Estazolam (DB01215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estazolam tablets (1 mg each day for 30 days) (Group C)
Study: 23986168
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of 36 Units of AbobotulinumtoxinA (ABO) into the middle of the lateral orbital rhytides
Study: 23986168
Drug: Three intradermal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three intradermal injections of 12 Units each of AbobotulinumtoxinA (ABO) along the lateral canthal area
Study: 18467912
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg) bid and amoxicillin (1000 mg) bid and clarithromycin (500 mg) bid for 1 week, followed by placebo for 3 weeks (EAC and placebo)
Study: 18467912
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg) bid and amoxicillin (1000 mg) bid and clarithromycin (500 mg) bid for 1 week, followed by esomeprazole (20 mg) once daily for 3 weeks (EAC and E20)
Study: 18467912
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg) once daily for 3 weeks after 1 week of esomeprazole (20 mg) bid and placebo antimicrobials (E20 bid and E20)
Study: 16615116
Drug: Cereal supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal supplement containing folic acid and wheat bran fiber (WBF)
Study: 1554120
Drug: Propofol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (10 mg = 1 mL)
Study: 1554120
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL Intralipid)
Study: 28575484
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (transfusion trigger < 10 g/dL, Group 1)
Study: 28575484
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (transfusion trigger ≤ 7 g/dL, Group 2)
Study: 26563117
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g L-arginine supplementation
Study: 26563117
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no L-arginine supplementation)
Study: 22614148
Drug: 6 g·d⁻¹
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g·d⁻¹ CLA
Study: 20456751
Drug: Bemiparin (3500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemiparin (3500 IU subcutaneously once daily for 8 days, followed by bemiparin for 20 additional days)
Study: 15592872
Drug: IgG(4) antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG(4) antibodies to mink and silver fox urine
Study: 15592872
Drug: IgG(4) antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG(4) antibodies
Study: 7793402
Drug: Low-dose amiodarone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amiodarone (mean maintenance dose 268 ± 100 mg/day)
Study: 1323545
Drug: Phenylpropanolamine (PPA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine (PPA), 75 mg sustained release
Study: 364616
Drug: Ketoprofen (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (75 mg daily orally and 100 mg suppository at night)
Study: 364616
Drug: Indomethacin (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (same dosage as ketoprofen)
Study: 30910144
Drug: Eryngo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eryngo (5 ml syrup, 3 times a day for 5 days)
Study: 30910144
Drug: Ibuprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (200 mg, 3 times a day for 5 days)
Study: 30910144
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml syrup, 3 times a day for 5 days)
Study: 15253848
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (5 weeks, 10 sessions, 10-15 needle insertions per session, needles left in situ for 30-45 minutes)
Study: 9192551
Drug: E2 protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 protocol (oral care instructions at 1 week before radiotherapy)